SAB Biotherapeutics Inc SABS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-01-12 |
| Shares Out. | 76,460,000 |
| Website | sab.bio/ ↗ |
| Phone | 13026365400 |
| Employees | 86 |
| Net Income | -$18.9M |
| Free Cash Flow | -$53.2M |
| Total Assets | $248.5M |
| Total Liabilities | $21.2M |
| Equity | $227.2M |
About SAB Biotherapeutics Inc
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
SAB Biotherapeutics Inc is a publicly traded company under the ticker symbol SABS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)